Risperdal Lawsuit Trial Continues, as Bernstein Liebhard LLP Comments on Testimony Pertaining to Handling of Gynecomastia Data

Share Article

The Firm is representing numerous Risperdal gynecomastia plaintiffs who have cases pending in the same Pennsylvania litigation

Free Case Review
We are following this bellwether trial closely, as the jury’s decision in this case could provide insight into jury rulings in similar Risperdal lawsuits.

Testimony continued Thursday in an important Risperdal lawsuit (http://www.risperdallawsuit2014.com/) trial now underway in Pennsylvania’s Philadelphia Court of Common Pleas, one of hundreds that have been filed in the state’s mass tort litigation, Bernstein Liebhard LLP reports. Court records indicate that for a second day, jurors heard from Dr. David Kessler, a former U.S. Food & Drug Administration (FDA), who is presenting expert testimony on behalf of the Plaintiff, a 20-year-old autistic man who allegedly developed female-like breasts due to his use of Risperdal as an 8-year-old boy. According to court documents, Dr. Kessler’s testimony on Thursday focused on alleged attempts by Johnson & Johnson’s Janssen Pharmaceuticals division to conceal a link between Risperdal and male breast growth. In particular, Kessler asserted that company emails and manuscripts pertaining to a 2001 study suggested an effort to reanalyze data in order to downplay the risk of gynecomastia. (Case No. 1204-01997)

“Our Firm is representing numerous Risperdal gynecomastia plaintiffs in this litigation who also claim that the drug’s manufacturers concealed information about its association with male breast growth. We are following this bellwether trial closely, as the jury’s decision in this case could provide insight into jury rulings in similar Risperdal lawsuits,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to men and boys who allegedly developed gynecomastia due to their use of Risperdal.

Risperdal Litigation
According to court documents, more than 1,200 Risperdal lawsuits are now pending in the Pennsylvania litigation, all of which allege that Johnson & Johnson and Janssen failed to provide patients with adequate warnings about its association with a number of serious complications, including gynecomastia. Specifically, Risperdal gynecomastia plaintiffs claim that the drug’s manufacturers concealed information about its effect on prolactin, a hormone that plays a role in female breast development and lactation. Excessive levels of prolactin in men and boys can also result in excessive breast growth, painful and swollen breasts, and nipple discharge, according to the lawsuits. (In Re: Risperdal Litigation, Case Number 100300296)

Court records indicate that these lawsuits are not the only legal action Johnson & Johnson and Janssen have faced over Risperdal. In November 2013, for example, the companies reached an agreement with the U.S. Department of Justice to pay $2.2 billion to settle criminal and civil charges regarding the marketing of several medications, including Risperdal. While they did plead guilty to promoting Risperdal for off-label use in elderly dementia patients, the companies did not concede to any wrongdoing in resolving any of the other allegations, including claims that they had marketed Risperdal for autism and other off-label pediatric indications prior to their 2006 FDA approval. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)

Men and boys who allegedly developed gynecomastia due to Risperdal may be entitled to pursue their own claim against Johnson & Johnson and Janssen. To learn more about filing a Risperdal lawsuit, please visit Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com
http://www.risperdallawsuit2014.com/
https://plus.google.com/115936073311125306742?rel=author

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Follow us on
Visit website